Search Intelligence

"When a biotech loses its mega-cap pharma lifeline, aggressive cash conservation through mass layoffs is just the first step in delaying the inevitable."

"Releasing an expert-level diagnostic model as open-source isn't just charity; it's a brute-force strategy to bypass legacy medical software vendors and dominate global hospital workflows."

"Thyme Care is using its navigation software as a wedge to roll up the far more lucrative clinical trial and biosimilar supply chains."

"Markets treated a single clinical trial readout like an instant revenue pipeline before remembering late-stage drug commercialization takes years of cash burn."

"Validating therapeutic mRNA in Phase 3 is a major step forward, though evaluating the clinical effect size requires published trial data."

"The industry's spent the last year trying to build one omniscient model, but the real moat is wiring thousands of narrow bots together to argue until they figure a cure out."

"So a $111.7 million IPO is barely enough capital to get a phase 2 oncology trial paid for."